Pediatric Nephrology

, Volume 21, Issue 6, pp 807–810 | Cite as

Influence of oral intake of Saccharomyces boulardii on Escherichia coli in enteric flora

  • Ipek AkilEmail author
  • Ozge Yilmaz
  • Semra Kurutepe
  • Kenan Degerli
  • Salih Kavukcu
Original Article


Enteric flora constitutes 95% of the cells in the human body. It has been shown that the bacterial content of this flora is affected by diet and changes in nutrition. Considering that urinary tract infections (UTI) are mostly due to ascending infections from the gut flora, the importance of the elements of this flora and their characteristics becomes more evident. The aim of this study was to evaluate the influence of oral Saccharomyces boulardii (S. boulardii) intake on the number of Escherichia coli (E. coli) colonies in the colon. This study was carried out with 14 boys and 10 girls (total of 24 children) aged between 36 and 192 months (mean: 104.3±45.1 months). A commercial capsule or powder containing 5 billion colony-forming units (cfu) of S. boulardii was administered once a day for 5 days. The number of E. coli and yeast colonies was measured in the stool samples of the study group before and after the use of this drug. Before treatment, the mean number of E. coli colonies in g/ml stool was 384,625±445,744. This number decreased significantly to 6,283±20,283 after treatment (p=0.00). S. boulardii was not detected in stool before treatment and the number of colonies increased to 11,047±26,754 in g/ml stool. S. boulardii may be effective in reducing the number of E. coli colonies in stool. The influence of this finding on clinical practice such as prevention of UTI needs to be clarified by further studies.


Saccharomyces boulardii Urinary tract infection Prevention Escherichia coli 


  1. 1.
    Stull TL, LiPuma JJ (1991) Epidemiology and natural history of urinary tract infections in children. Med Clin North Am 75:287–297CrossRefGoogle Scholar
  2. 2.
    Dunne C, O’Mahony L, Murphy L, Thornton G, Morrissey D, O’Halloran S, Feeney M, Flynn S, Fitzgerald G, Daly C, Kiely B, O’Sullivan GC, Shanahan F, Collins JK (2001) In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr 73:386S–392SCrossRefGoogle Scholar
  3. 3.
    Elmer GW, Surawicz CM, McFarland LV (1996) Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 275:870–876CrossRefGoogle Scholar
  4. 4.
    McFarland LV, Elmer GW (1995) Biotherapeutic agents: past, present and future. Microecology Ther 23:46–73Google Scholar
  5. 5.
    McFarland LV, Bernasconi P (1993) Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis 6:157–171CrossRefGoogle Scholar
  6. 6.
    Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P (2000) Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 68:5998–6004CrossRefGoogle Scholar
  7. 7.
    Kontiokari T, Nuutinen M, Uhari M (2004) Dietary factors affecting susceptibility to urinary tract infection. Pediatr Nephrol 19:378–383CrossRefGoogle Scholar
  8. 8.
    Reid G (2001) Probiotic agents to protect the urogenital tract against infection. Am J Clin Nutr 73(Suppl):437S–443SCrossRefGoogle Scholar
  9. 9.
    Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF (2002) Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 82:103–108CrossRefGoogle Scholar
  10. 10.
    Mombelli B, Gismondo MR (2000) The use of probiotics in medical practice. Int J Antimicrob Agents 16:531–536CrossRefGoogle Scholar
  11. 11.
    Dahan S, Dalmasso G, Imbert V, Peyron JF, Rampal P, Czerucka D (2003) Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 71:766–773CrossRefGoogle Scholar
  12. 12.
    Rodrigues AC, Cara DC, Fretez SH, Cunha FQ, Vieira EC, Nicoli JR, Vieira LQ (2000) Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol 89:404–414CrossRefGoogle Scholar
  13. 13.
    Reid G, Burton J (2002) Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect 4:319–324CrossRefGoogle Scholar
  14. 14.
    Howell AB, Vorsa N, Der Marderosian A, Foo LY (1998) Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. N Engl J Med 339:1085–1086CrossRefGoogle Scholar
  15. 15.
    Burkhardt O, Kohnlein T, Pletz M, Welte T (2005) Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. Scand J Infect Dis 37:69–71CrossRefGoogle Scholar
  16. 16.
    Schlager TA, Hendley JO, Bell AL, Whittam TS (2002) Clonal diversity of Escherichia coli colonizing stools and urinary tracts of young children. Infect Immun 70:1225–1229CrossRefGoogle Scholar
  17. 17.
    Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M (2001) Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 322:1571–1573CrossRefGoogle Scholar
  18. 18.
    Reid G, Bruce AW, Taylor M (1992) Influence of three-day antimicrobial therapy and lactobacillus vaginal suppositories on recurrence of urinary tract infections. Clin Ther 14:11–16PubMedGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Ipek Akil
    • 1
    • 4
    Email author
  • Ozge Yilmaz
    • 1
  • Semra Kurutepe
    • 2
  • Kenan Degerli
    • 2
  • Salih Kavukcu
    • 3
  1. 1.Department of Pediatric NephrologyCelal Bayar UniversityManisaTurkey
  2. 2.Department of MicrobiologyCelal Bayar UniversityManisaTurkey
  3. 3.Department of Pediatric NephrologyDokuz Eylül UniversityIzmirTurkey
  4. 4.IzmirTurkey

Personalised recommendations